FGF23 and myocardial infarction: However, underpathological conditions, other cell types such as immune cells in systemic inflammatoryprocesses (Masuda et al. 2015) orcardiomyocytes after experimental myocardial infarction or in patients with left ventricularhypertrophy (Andrukhova et al.2015; Leifheit-Nestler et al.2016) may become relevant sources of circulating FGF23.